[1] 葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:166
[2] 中华医学会心血管病分会,中华心血管病杂志编辑委员会.中国心力衰竭诊断与治疗指南2014[J].中华心血管病杂志,2014,42(2):98 [3] Givertz MM,Mann DL,Lee KL,et al. Xanthine oxidase inhibition for hyperuricemic hert fdilure patients: design and rationale of the EXACF-HF study[J]. Circ Hert Fail,2013,6(4):862 [4 ] 蔡金,黄全跃.新兴的心力衰竭生物标记物[J].心血管病学进展,2014,35(1):193 [5 ] 黄国鹏,安素.N末端B型利钠肽原对老年心力衰竭临床应用价值的研究[J].中国循环杂志,2014,29(9):698 [6] Nagele H,Bahlo M, Klapdor R, et al. CA125 and its relation to cardiac function[J]. Am Heart J ,1999,137(6):1044 [7] 马超,邓旭康,朱海清.血清CA125水平与慢性充血性心力衰竭的相关性研究[J].齐齐哈尔医学院学报,2013,34(12):1736 [8] Anker SD,Cldrk AL,Winker R,et al. Statin use and survival in Patients with ehronic heart failure results form two observational studies with 5200 Patients[J]. Int J Cardiol, 2006,112(2):234 [9 ] Kuboniski L,Bandobashi K,Murata N,et al. High serum levers of CA125 and interleukin-6 in a patient with Ki-1 lymphoma[J]. Br J Hatmatol,1997,98(2):450 [10] Dursun Duman,Fatih Palit,Ergun Simsek,et al. Serum carbohydrate antigen 125 levels in advanced heart failure: Relation to B-Tyee natriuretic peptide and left atrial volume[J]. Europ J Heart Fail,2009,10(6):516 [11] 汤建,周爱儒.原癌基因与心血管病[M]. 北京:北京医科大学、中国协和医科大学联合出版社,1990:176 [12 ]那剑,白元,秦永文.新型心率衰竭标记物-CA125[J].心血管病学进展,2014,35(2):193 [13 ] 高杨,胡元会.心力衰竭中血清糖类抗原125变化的研究进展[J].中西医结合心脑血管病杂志,2012,10(2):213 [14] 马瑞,桂静,彭松,等.外周血清糖类抗原125水平与不同病因心力衰竭B型钠尿肽水平及心功能的相关性研究[J].实用心脑肺血管病杂志,2013,21(9):22
[1]尹新军,王贝贝,李新建,等.白芍总苷调控Sirt1/Foxo1通路对慢性心力衰竭大鼠的保护作用研究[J].天津医科大学学报,2021,27(01):6.
YIN Xin-jun,WANG Bei-bei,LI Xin-jian,et al.Protective effect of total glucosides of paeonia regulating Sirt1/Foxo1 pathway on rats with chronic heart failure[J].Journal of Tianjin Medical University,2021,27(05):6.
[2]郭晓亮,袁宇,段长恩.ADAMTs-1、CF6、CARP在冠心病合并慢性心力衰竭中的意义[J].天津医科大学学报,2021,27(04):329.
GUO Xiao-liang,YUAN Yu,DUAN Chang-en.Significance of ADAMTs-1,CF6 and CARP in coronary heart disease complicated with chronic heart failure[J].Journal of Tianjin Medical University,2021,27(05):329.